Rockefeller Capital Management L.P. Boosts Stake in Viking Therapeutics, Inc. $VKTX

Rockefeller Capital Management L.P. boosted its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 38.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 53,053 shares of the biotechnology company’s stock after purchasing an additional 14,772 shares during the period. Rockefeller Capital Management L.P.’s holdings in Viking Therapeutics were worth $1,866,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Raleigh Capital Management Inc. lifted its stake in Viking Therapeutics by 58.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 945 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 347 shares in the last quarter. Quattro Advisors LLC acquired a new stake in shares of Viking Therapeutics in the fourth quarter valued at $37,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Viking Therapeutics in the third quarter valued at $38,000. Fifth Third Bancorp raised its holdings in shares of Viking Therapeutics by 169.2% in the 4th quarter. Fifth Third Bancorp now owns 1,077 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 677 shares during the period. Finally, Lodestone Wealth Management LLC purchased a new stake in shares of Viking Therapeutics in the 4th quarter valued at $39,000. Hedge funds and other institutional investors own 76.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on VKTX shares. BTIG Research restated a “buy” rating and set a $125.00 target price on shares of Viking Therapeutics in a report on Friday, May 1st. Cantor Fitzgerald cut their price target on shares of Viking Therapeutics from $105.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Truist Financial began coverage on shares of Viking Therapeutics in a research report on Wednesday, May 27th. They set a “buy” rating and a $83.00 price target on the stock. Lake Street Capital began coverage on shares of Viking Therapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $89.00 price objective for the company. Finally, Wolfe Research assumed coverage on shares of Viking Therapeutics in a report on Thursday, March 26th. They issued a “peer perform” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Viking Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $93.60.

Viking Therapeutics Trading Down 1.3%

Shares of NASDAQ VKTX opened at $39.01 on Wednesday. The stock has a market cap of $4.53 billion, a P/E ratio of -9.42 and a beta of 0.69. Viking Therapeutics, Inc. has a 12-month low of $22.96 and a 12-month high of $43.15. The business’s fifty day simple moving average is $31.75 and its 200-day simple moving average is $32.65.

Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Thursday, April 30th. The biotechnology company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.36). During the same quarter in the previous year, the firm posted ($0.41) earnings per share. On average, equities analysts forecast that Viking Therapeutics, Inc. will post -4.7 EPS for the current fiscal year.

Viking Therapeutics Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.